Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + thalidomide + rituximab
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous (bortezomib), Oral (thalidomide), Intravenous (rituximab)
01
Overview
This combination involves **bortezomib**, a proteasome inhibitor; **thalidomide**, an immunomodulatory drug; and **rituximab**, a monoclonal antibody targeting CD20. It is used in the treatment of certain cancers, including lymphomas and multiple myeloma. The mechanism of action involves inhibiting proteasome function, modulating immune responses, and targeting B cells.
- Other names
- 硼替佐米 + 沙利度胺 + 利妥昔单抗
02
Targets
PSMB5 (Proteasome subunit beta Type-5)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on bortezomib + thalidomide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + thalidomide + rituximab.